Close Menu

GenScript

The Harvard spinout wants its instrumentation and reagent packages to ease the transition for labs interested in high-resolution imaging studies.

The San Diego-based DNA synthesis firm this week announced $12.2 million in Series A funding, but has plans to expand the round.

GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.

The La Jolla, California-based firm is moving beyond its US home market into other regions that promise growth for synthetic genomics providers.

NEW YORK (GenomeWeb News) – Roche said this week that it will invest CHF 240 million ($258.4 million) in a new diagnostics center at its Penzberg, Germany biotech center near Munich.

NEW YORK (GenomeWeb News) – Almac Diagnostics said this week that it has launched a next-generation sequencing service to its portfolio, which also includes microarray, qPCR, and immunohistochemical offerings.

Patent watchdog firm Troll Busters has chosen to abandon its lawsuit against more than a dozen life science companies for false patent marking related to various nucleic acid detection, amplification, and cloning technologies, according to recently filed court documents.

The firms intend to develop next-generation proteins and enzymes based on synthetic biology.

New Products: Sep 3, 2010

Premium

Shimadzu, HealthLinx, Protein Discovery, GenScript

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.